ClinicalTrials.gg
Not yet recruitingNCT07509879WS and ASDUpdated Apr 3, 2026

Research on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder

An observational study in Williams Syndrome and Autism Disorder, sponsored by Qilu Hospital of Shandong University. Not yet recruiting at 1 site in China. Open to participants aged 3 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Qilu Hospital of Shandong University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
75
Ages
3 Years to 12 Years
Sex
All
01

Study summary

Williams Syndrome (WS) is a rare neurodevelopmental disorder, usually caused by microdeletions of approximately 26 genes in the long arm (7q11.23) region of chromosome 7. Children with this syndrome often exhibit distinctive facial features, mild to moderate intellectual disability, impaired spatial cognition, pronounced social extraversion, and relatively reserved language-expression characteristics. Although individuals with WS often demonstrate strong social interest and prosocial behaviors, significant deficiencies in abstract thinking, executive function, and visuospatial ability are frequently observed. At present, treatment for WS mainly focuses on behavioral intervention and educational rehabilitation, and clear molecular or pharmacological treatment methods remain limited. Due to the "opposite but related" social-cognitive profile observed in comparison with autism spectrum disorder, in-depth exploration of neural and molecular mechanisms underlying these differences has substantial scientific significance for understanding the biological basis of social-cognitive impairment.

02

Conditions studied

  • Williams Syndrome
  • Autism Disorder

Keywords

  • Williams Syndrome
  • Autism Spectrum Disorder
  • Neuroimaging
  • Genetics
03

In context

Williams Syndrome

29 studies on the registry are indexed under Williams Syndrome; 11 are open to participants now.

This study's planned enrollment of 75 is below the median of 100 across 15 observational studies indexed under Williams Syndrome.

Browse Williams Syndrome studies →

Lead sponsor

Qilu Hospital of Shandong University is the lead sponsor of 311 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Source of research participants: WS research participants, ASD research participants and normal children controls who visited the pediatric health rehabilitation clinic

Eligibility criteria

Participants for Williams Syndrome Study

Inclusion criteria must all be met:

  1. Age 3-12 years old.
  2. Clinically diagnosed and confirmed by fluorescence in situ hybridization (FISH) test, with a typical microdeletion of approximately 1.55 Mb in the chromosome 7q11.23 region.
  3. Their legal guardians fully understand the study content and voluntarily sign the form, agreeing for the study participants to undergo blood sampling and genetic testing.

Participants for Autism Spectrum Disorder Study

Inclusion criteria must all be met:

  1. Age 3-12 years old.
  2. Clinically diagnosed according to the second edition of the Autism Diagnostic Observation Schedule (ADOS-2) criteria.
  3. Their legal guardians fully understand the study content and voluntarily sign the informed consent form, agreeing for the study participants to undergo blood sampling and genetic testing.

Participants for Healthy Children Study

Inclusion criteria must all be met:

  1. Age 3-12 years old, with gender as close as possible to the participants in the above two groups.
  2. No history of neurodevelopmental disorders, mental illnesses or major neurological diseases.
  3. Their legal guardians fully understand the study content and voluntarily sign the informed consent form, agreeing for the study participants to undergo blood sampling and genetic testing.

Common Exclusion Criteria for All Study Participants

Any of the following conditions must be met to be excluded from the study:

  1. Specific medical conditions:
  2. For the Williams Syndrome group: Known or suspected presence of other pathogenic gene mutations/syndromes other than the 7q11.23 microdeletion.
  3. For the Autism Spectrum Disorder group: Co-occurring other clearly diagnosed neurodevelopmental disorders (such as Rett syndrome, fragile X syndrome, etc.).
  4. Brain structural abnormalities: According to recent cranial MRI and interpretation by neuro-radiology experts, significant brain structural lesions are found (for the patient group, referring to lesions unrelated to Williams Syndrome or autism; for the healthy group, referring to any abnormalities).
  5. Major systemic diseases: Presence of diseases with clinical significance as judged by the researchers, which may: affect the interpretation of study results, or endanger the safety of the study participants.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
75 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Williams Syndrome

    After clinical diagnosis and confirmation through fluorescence in situ hybridization (FISH) testing, a typical microdeletion of approximately 1.55 Mb in the chromosome 7q11.23 region was identified.

  • Autism Spectrum disorder

    It meets the clinical diagnostic criteria of the Second Edition of the Autism Diagnostic Observation Scale (ADOS-2).

  • healthy children

    There is no history of neurodevelopmental disorders, mental illness or major neurological diseases

06

What researchers measure

Primary outcomes

  1. The score of Motor Quotient in Peabody Developmental Motor Scales, Second Edition (PDMS-2)

    Motor development will be assessed using the Peabody Developmental Motor Scales, Second Edition (PDMS-2). The endpoint is the Motor Quotient (range: 50-150). Higher scores indicate better motor functioning (i.e., better outcome). Group differences will be evaluated across WS, ASD, and typically developing controls.

    Time frame: Baseline

  2. The score of Developmental Quotient (DQ) in Gesell Developmental Schedules (GDS)

    Neurodevelopmental level will be assessed using the Gesell Developmental Schedules (Gesell Developmental Scale). The endpoint is the Developmental Quotient (DQ) (range: 0-130). Higher scores indicate better developmental functioning (i.e., better outcome). Group differences will be evaluated across WS, ASD, and typically developing controls.

    Time frame: Baseline

  3. Fractional Anisotropy (FA)

    White matter microstructural integrity will be quantified using DTI-derived fractional anisotropy (FA). FA values range from 0 to 1, with higher values indicating greater directional diffusion and typically better white matter integrity (i.e., better outcome). Group differences will be evaluated across WS, ASD, and typically developing controls. Unit of Measure : mm²/s (typically reported as ×10-³ mm²/s)

    Time frame: baseline

  4. The score pf Social Responsiveness Scale, Second Edition (SRS-2)

    Social communication will be assessed using the Social Responsiveness Scale, Second Edition (SRS-2). The primary endpoint is the SCI T-score (range: 0-100). Higher scores indicate worse social communication impairment (i.e., poorer outcome). Group differences will be compared across WS, ASD, and typically developing controls.

    Time frame: baseline

Secondary outcomes

  1. Diffusion Tensor Imaging (DTI) Axial Diffusivity (AD)

    White matter microstructural properties will be quantified using DTI-derived axial diffusivity (AD). AD will be summarized as the mean AD within prespecified white matter regions of interest (ROIs) (or whole-brain white matter skeleton, if applicable). Higher AD indicates greater diffusion along the principal axis; interpretation (better/worse) is direction-dependent and will be interpreted in the context of neurodevelopmental findings. Unit of Measure: mm²/s (typically reported as ×10-³ mm²/s)

    Time frame: Baseline

  2. Diffusion Tensor Imaging (DTI) Mean Diffusivity (MD)

    DTI-derived mean diffusivity (MD) will be calculated and summarized as the mean MD within prespecified white matter ROIs (or whole-brain white matter skeleton, if applicable). Higher MD indicates greater overall water diffusion and is commonly interpreted as reduced microstructural integrity (worse outcome). Unit of Measure: mm²/s (typically reported as ×10-³ mm²/s)

    Time frame: Baseline

  3. Diffusion Tensor Imaging (DTI) Radial Diffusivity (RD)

    DTI-derived radial diffusivity (RD) will be calculated and summarized as the mean RD within prespecified white matter ROIs (or whole-brain white matter skeleton, if applicable). Higher RD indicates greater diffusion perpendicular to the principal axis and is often interpreted as poorer myelination or reduced microstructural integrity (worse outcome).Unit of Measure: mm²/s (typically reported as ×10-³ mm²/s)

    Time frame: Baseline

  4. Structural MRI (sMRI) Cortical Volume

    Cortical morphology will be quantified from T1-weighted structural MRI. Cortical volume will be computed using an automated cortical reconstruction pipeline (e.g., FreeSurfer) and summarized as mean cortical volume (mm³) within prespecified cortical ROIs (or total cortical gray matter volume, if applicable). Higher cortical volume indicates greater cortical tissue volume. Unit of Measure: mm³

    Time frame: Baseline

  5. Structural MRI (sMRI) Cortical Thickness

    Cortical morphology will be quantified from T1-weighted structural MRI. Cortical thickness will be computed and summarized as mean cortical thickness (mm) within prespecified cortical ROIs (or mean global cortical thickness, if applicable). Higher thickness indicates greater cortical thickness;Unit of Measure: mm

    Time frame: Baseline

  6. Structural MRI (sMRI) Subcortical Structure Volume

    Subcortical anatomy will be quantified from T1-weighted structural MRI. Subcortical structure volumes (e.g., amygdala, hippocampus, thalamus, caudate, putamen, pallidum) will be computed using an automated segmentation pipeline (e.g., FreeSurfer) and summarized as volume (mm³) for prespecified subcortical regions. Higher volume indicates greater structure volume; Unit of Measure: mm³

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Apr 3, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07509879
Responsible party
Sponsor
First posted
Apr 3, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion